September 19, 2023
Analysts play a crucial role in the stock market by evaluating specific stocks or sectors and providing ratings to guide investors. These ratings are typically updated quarterly and are based on a variety of sources, including company conference calls, financial statements, and insider conversations. In addition to their ratings, analysts often make predictions for various metrics such as growth estimates, earnings, and revenue, offering further insights to investors.
When it comes to Boston Scientific (NYSE:BSX), analysts have recently shared their ratings for the stock. Within the last quarter, 10 analysts have expressed a bullish outlook, indicating a positive sentiment towards the company. Furthermore, 7 analysts have shown a somewhat bullish stance, suggesting a moderately positive view. On the other hand, 2 analysts have remained indifferent, neither leaning towards positivity nor negativity. Notably, there have been no somewhat bearish or bearish ratings, indicating a lack of negative sentiment among the analysts.
Considering the collective opinions of these 19 analysts, the average price target for Boston Scientific stands at $60.42. This is notably higher than the current price of the stock, which is $52.975, implying a potential upside. It is worth mentioning that the average price target has experienced a 3.28% increase over the past month, reflecting a growing optimism among analysts.
Overall, the ratings and predictions provided by analysts serve as valuable guidance for investors, helping them make informed decisions in the dynamic world of the stock market.
Boston Scientific Corporation
BSX
Strong Buy
Updated on: 29/09/2023
Financial Health
Very Healthy
Debt to equity ratio: Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Neutral
BSX Stock Performance and Analysis: September 19, 2023
BSX (Becton Dickinson and Company) stock experienced a slight increase in performance on September 19, 2023. The stock opened at $53.01, slightly higher than the previous day’s closing price of $53.00. Throughout the day, the stock fluctuated within a range of $52.58 to $53.18. The trading volume was 7,517,461 shares.
BSX has a market capitalization of $77.5 billion. The company’s earnings growth has been mixed, with a decline of 35.19% in the previous year but a positive growth of 14.41% expected for this year. Analysts predict a growth rate of 12.10% for the next five years.
In terms of revenue growth, BSX experienced a positive growth rate of 6.68% in the last year. The price-to-earnings (P/E) ratio for BSX is 88.4. The price/sales ratio is 5.25, and the price/book ratio is 4.31.
On September 19, 2023, other companies in the medical distribution industry experienced mixed performance. BDX (Becton Dickinson and Company) saw an increase of 0.52% in its stock price, while DXCM (Dexcom Inc) declined by 1.15%. WST (West Pharmaceutical Services) also experienced a decrease of 0.54%, and ZBH (Zimmer Biomet Holdings) saw a small decline of 0.34%.
Looking ahead, BSX’s next reporting date is October 26, 2023. Analysts forecast an earnings per share (EPS) of $0.48 for this quarter. In the previous year, the company reported an annual revenue of $12.7 billion and a profit of $698.0 million. The net profit margin for BSX is 5.50%.
BSX operates in the distribution services sector within the medical distributors industry. The company is headquartered in Marlborough, Massachusetts.
Overall, BSX stock had a relatively stable performance on September 19, 2023. The company’s earnings growth has been mixed but is expected to improve in the coming years. With a positive revenue growth rate and a reasonable profit margin, BSX appears to be a solid player in the medical distribution industry. However, investors should consider the valuation ratios and industry trends before making any investment decisions.
Promising Performance and Positive Outlook: Analyzing BSX Stock and Boston Scientific Corp for Investment Opportunities
BSX stock has shown promising performance on September 19, 2023. The 28 analysts offering 12-month price forecasts for BSX have a median target of 60.50, with a high estimate of 68.00 and a low estimate of 55.00. This represents a 14.11% increase from the last price of 53.02.
The current consensus among 32 polled investment analysts is to buy stock in Boston Scientific Corp. This rating has remained steady since August.
Boston Scientific Corp reported earnings per share of $0.48 for the current quarter. Additionally, the company reported sales of $3.4 billion for the same period.
Investors should keep an eye on Boston Scientific Corp as it approaches its reporting date of October 26.
Overall, the market outlook for BSX stock appears positive. Analysts have projected a significant increase in the stock’s price over the next 12 months, and the consensus among investment analysts is to buy the stock. Boston Scientific Corp seems to be a promising investment option.
Discussion about this post